Cellectis (CLLS) to Release Quarterly Earnings on Monday

Cellectis (NASDAQ:CLLS) is expected to release its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect Cellectis to post earnings of ($0.2583) per share and revenue of $11.0390 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Monday, May 11, 2026 at 2:00 AM ET.

Cellectis (NASDAQ:CLLS) last announced its earnings results on Thursday, March 19th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.16). The firm had revenue of $15.50 million during the quarter, compared to analyst estimates of $10.74 million. Cellectis had a negative net margin of 84.92% and a negative return on equity of 69.38%.

Cellectis Stock Up 4.7%

CLLS traded up $0.18 during trading on Wednesday, hitting $3.94. The stock had a trading volume of 2,461 shares, compared to its average volume of 41,924. The company has a market capitalization of $394.84 million, a PE ratio of -5.87 and a beta of 2.94. Cellectis has a twelve month low of $1.33 and a twelve month high of $5.48. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.62 and a current ratio of 1.62. The stock has a 50 day simple moving average of $3.69 and a two-hundred day simple moving average of $4.01.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CLLS. Global Retirement Partners LLC acquired a new position in Cellectis during the fourth quarter valued at $34,000. Acadian Asset Management LLC increased its holdings in Cellectis by 132.9% in the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 26,461 shares in the last quarter. Virtu Financial LLC purchased a new position in Cellectis in the third quarter valued at $72,000. Millennium Management LLC increased its holdings in Cellectis by 61.9% in the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 22,080 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new position in Cellectis in the third quarter valued at $633,000. 63.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on CLLS shares. Jefferies Financial Group started coverage on Cellectis in a research note on Tuesday, February 17th. They issued a “buy” rating and a $7.00 target price for the company. Citizens Jmp restated a “market outperform” rating and issued a $8.00 target price on shares of Cellectis in a research note on Tuesday, April 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a research note on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $6.75.

Cellectis Company Profile

Cellectis is a clinical?stage biopharmaceutical company specializing in the development of gene?edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T?cell (CAR?T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off?the?shelf immunotherapies.